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EDITORIAL REVIEW
Circulating DNA and lupus nephritis
Historical perspective
The association between antibodies directed against nuclear
antigens and systemic lupus erythematosus (SLE) has been well
established since the discovery 40 years ago of the "LE cell"
[1]. Antibodies directed against deoxyribonucleic acid (DNA,
anti-DNA Ab) were later characterized in sera from lupus
patients [2—5] as well as from (NZBxNZW) mice [6, 7] which
spontaneously develop an immune complex type of glomerulo-
nephritis [8, 9]. Granular deposits of immunoglobulin and
complement were found in glomeruli of kidneys from lupus
patients with nephritis [10, 11] and from NZBxNZW mice [12].
Anti-DNA Ab were rapidly recognized as participants in patho-
genic mechanisms leading to the kidney disease seen in lupus
patients. However, several studies have shown they were not,
by themselves, pathogenic in vivo [13, 14] or cytotoxic to tissue
culture cells in vitro [15, 16]. In addition, clinical as well as
experimental studies strongly suggested that anti-DNA Ab
played their pathogenic role through the formation of DNA-
anti-DNA immune complexes, and that these complexes repre-
sented the main pathogenic immune complex system at work in
the development of lupus nephritis [17, 18].
Between 1950 and 1960, studies done on the serum sickness
model in rabbits [19, 20] provided evidence that glomerular
injury might result from the deposition in glomeruli of immune
complexes formed in the circulation [211, supplanting the most
widely accepted view of the time that, as in the Arthus reaction,
the nephritogenic antigens fix in tissue before reacting with
antibodies to produce disease [22]. In the absence of any other
well studied experimental model, most cases of human immune
complex glomerulonephritis were thought to be induced by the
deposition of circulating immune complexes. In lupus patients,
as well as in (NZBxNZW) mice, it was postulated that circu-
lating DNA-anti-DNA immune complexes in antigen excess
were responsible for the development of glomerular lesions.
Then came the time of contradictory results. As soon as
suitable assays became available [23, 24] circulating immune
complexes were frequently found in sera from lupus patients
[24, 25], but attempts to identify DNA-anti-DNA were variable
and confusing. It was suggested that, if present, they repre-
sented at most a few percent of the total pool of immune
complexes which circulated in these patients [26]. At the same
time much work was devoted to both the antibody and the
antigenic components of DNA-anti-DNA complexes. A great
deal was learned about the physicochemical and immunologic
properties of anti-DNA Ab, in part with the help of monoclonal
antibodies [27, 28]. On the other hand, data on extracellular
DNA appeared contradictory. First, mainly for technical rea-
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sons [29], no agreement was gained on the levels and immuno-
chemical characteristics of extracellular DNA which might
circulate in the blood of lupus patients and normals. Secondly,
no data supporting the view that extracellular DNA and anti-
DNA Ab can form complexes in blood and/or in kidney could
be obtained, despite many attempts in various experimental
models. Thirdly, data obtained on the catabolism of extracellu-
lar DNA in vivo clearly indicated that exogenous purified DNA
cannot circulate for more than a few minutes and was cleared
from circulation by efficient metabolic pathways in normal as
well as in lupus mice [30—34]. However, over the last ten years
substantial advances have been made in the field of circulating
DNA. Technical problems dealing with the study of plasma
DNA were clarified [35] and the enormous methodological
potential of molecular biology became available to study circu-
lating DNA in a new way [36]. Finally, the presence of
increased amounts of circulating DNA was clearly demon-
strated in well defined clinical and experimental situations other
than spontaneous lupus diseases [37, 38].
Today, two basic questions on circulating (extracellular)
DNA with respect to the physiopathology of lupus diseases are
still unanswered: (1) Is it responsible for the induction of
anti-DNA Ab? (2) Is it involved in the formation of immune
complexes in blood and/or tissues, and if so by which mecha-
nism? It is our hope that this review will clarify the current state
of our knowledge on circulating DNA in lupus and on its
potential pathogenic role in the development of tissue lesions,
particularly in glomeruli. First, the data supporting the view
that DNA-anti-DNA immune complexes are present in glomer-
uli from patients and mice with lupus diseases will be detailed.
Second, the mechanisms by which such immune complexes are
deposited in glomeruli as well as other possible pathogenic
mechanisms will be discussed. Third, data available on levels
and physicochemical characteristics of circulating DNA in
lupus diseases will be presented. Finally we will present and
discuss the ideas that cytolysis phenomena and chromatin
catabolism might be two main factors to be considered in the
pathogenesis of lupus nephritis.
DNA-anti-DNA immune complexes in lupus diseases
Arguments for the presence of DNA-anti-DNA immune
complexes in glomeruli from lupus patients and from
NZBxNZW mice
Immunoglobulin molecules reacting with nuclei were eluted
from the glomeruli of kidneys from patients with lupus nephritis
[39—41]. Shortly afterwards it was reported that one potential
antigen, DNA, was present in sera from certain patients with
active nephritis [42]. It was suggested that antigen-antibody
complexes composed of nuclear antigens and antinuclear anti-
bodies were involved in the pathogenesis of lupus nephritis.
The results of the study reported by Koffler et al in 1967 [43],
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supported such an hypothesis: first, quantitative immunochem-
ical studies revealed that immunoglobulins with antinuclear
activity eluted from kidneys of SLE patients were concentrated
in glomeruli as compared to antinuclear antibody in serum.
Other antibodies present in serum were not found in eluates.
Secondly, in some cases, granular deposits of DNA were found
in glomeruli after treatment of kidney sections with 2 M NaCl by
means of isolated anti-DNA Ab labelled with fluorescein. This
reaction was completely inhibited by treating the anti-DNA
conjugate with DNA. Attempts at demonstrating other nuclear
antigens with fluorescein conjugated anti-Sm or anti-nucleopro-
tein antibodies were unsuccessful.
Striking similarities between these findings and observations
done in the NZBxNZW murine model were reported by
Lambert and Dixon [7]. immunoglobulins (IgG) reacting with
nucleoproteins were found to be concentrated in eluates from
kidney homogeneates. While in the serum, antinuclear antibod-
ies appeared mainly directed against "insoluble" nucleopro-
tein, in the eluates they were predominantly directed against
DNA. Moreover, "DNA-like" antigens were found in glomer-
ular lesions. Besides these findings, other results from this
experimental work contributed to open the way to a new insight
in the pathophysiology of lupus nephritis: the development of
glomerulonephritis in NZBxNZW mice appeared closely re-
lated to the formation of antinuclear, particularly anti-DNA Ab
in blood and to the formation of DNA-anti-DNA immune
complexes; enhancement of the auto-immune response of
young NZBxNZW mice hastens the development and in-
creases the severity of the glomerular nephritis; intravenous
and intraperitoneal administration of DNA in NZBxNZW mice
with circulating anti-DNA Ab causes rapid progression of
nephritis. Moreover, immunochemical analysis revealed that
eluted IgG's belong in the main to the complement fixing IgG2
subclass, an observation which suggested a role for comple-
ment in the pathogenesis of lupus nephritis.
One of the major drawbacks of the works of Koffler et a! [43]
and of Lambert and Dixon [71 was the technical necessity to
treat the kidney sections with 2 M NaC1 at 37°C to detect
extracellular DNA antigens in glomeruli in order to avoid a
strong reaction of labelled anti-DNA Ab with cell nuclei. In two
elegant studies [44, 45], antisera to nucleosides were used to
detect DNA antigens in kidney sections. These antisera reacted
with denatured DNA (single stranded: ss DNA) but not with
native DNA (double stranded: ds DNA) nor with nuclei (except
at time of replication of DNA) [46]. Control groups were
included in both studies. In human pathology [44], glomerular
deposits of ss DNA were found in most patients with active
SLE glomerulonephritis and not in non-SLE patients with
similar histopathological lesions. They were also found in most
of the FT hybrids NZBxNZW lupus mice as compared to the
parental NZB and NZW mouse strains. Since in both human
and murine lupus diseases antibodies reacting with ss DNA or
with both ds and ss DNA were more frequently found than
antibodies reacting only with ds DNA [47], these results were
interpretated as supporting the hypothesis that DNA-anti-DNA
immune complexes were involved in the pathogenesis of lupus
nephritis.
In the light of experimental studies on the serum sickness
model and on the subsequent assertion that granular immuno-
globulins present in glomeruli resulted from the deposition of
circulating immune complexes, specific DNA-anti-DNA im-
mune complexes were therefore looked for in blood.
Controversy on the presence of circulating
DNA-anti-DNA complexes
The fact that DNA was a very well characterized antigen and
that it can be digested by specific enzymes provided the basis
for an assay able to detect DNA-anti-DNA complexes in sera.
Indeed, if enzyme digestion of DNA resulted in an increase of
detectable anti-DNA Ab, it can be assumed that the DNA
binding sites in the untreated serum must have been blocked in
vivo by DNA, leading to the conclusion that the serum con-
tained DNA-anti-DNA complexes. Using such a principle,
Harbeck et al [48] found that the majority of patients with active
lupus nephntis had circulating DNA-anti-DNA complexes and
that their occurrence in sera was correlated with the activity of
kidney disease. These results seemed to be further confirmed
[49], and were interpreted as providing the proof for the
presence and the pathogenic role of circulating DNA-anti-DNA
complexes in patients with lupus nephritis. Moreover, anti-
DNA Ab were found to be enriched in the cryoprecipitates from
lupus patients, and in many of them DNA was also detected
using the diphenylamine assay [50]. Taken together, all these
results were consistent with the previously reported works
suggesting the presence of DNA-anti-DNA immune complexes
in glomeruli as well as with the report by Natali and Tan [51] of
an experimental renal disease induced in rabbits immunized
against ultraviolet irradiated DNA (U V-DNA), by chronic
intravenous injections of UV-DNA.
The presence of circulating immune complexes in sera from
lupus patients, as reported by Nydegger and co-workers [24],
seemed to add further support to the hypothesis that circulating
DNA-anti-DNA complexes were involved in the pathogenesis
of SLE. In fact, while it was confirmed that increased levels of
circulating immune complexes were frequently found in sera of
lupus patients [52—54], further studies suggested that the fre-
quency of specific DNA-anti-DNA complexes detected in SLE
sera was overestimated [26, 55, 56]. Therefore the results
reported appeared contradictory. This might be explained in
two ways: (1) by the selection of patients studied; (2) by
technical bias related to the fact that these studies were done on
sera. (In a sample containing anti-DNA Ab, DNA-anti-DNA
complexes might be formed artefactually by the release of DNA
from leucocytes during clotting [35, 57]. In a later study done by
Bruneau and Benveniste using ultracentrifugation of plasma in
sucrose density gradient at physiologic and acid pHs, it was
shown that, after dissociation of high molecular weight mate-
rial, anti-DNA Ab could be recovered in many cases (14 of 24)
and low molecular weight DNA in a few cases (3 of 24) [58].
From all these data, it can be concluded that circulating
DNA-anti-DNA complexes do not occur frequently and repre-
sent only a small proportion of immune complexes present in
blood from lupus patients. This conclusion raised several ques-
tions: are DNA-anti-DNA immune complexes deposited in
glomeruli through a mechanism of local formation? Are these
complexes the major antigen-antibody pathogenic system in-
volved in lupus nephritis? Are anti-DNA Ab playing a patho-
genic role through a mechanism independent of the formation of
immune complexes?
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Are DNA-anti-DNA immune complexes formed locally in
glomeruli? Or in other words, is extracellular DNA planted in
glomeruli before it is bound to anti-DNA ab?
The possibility that DNA-anti-DNA complexes can localize
in glomeruli through other mechanisms than the direct deposi-
tion of circulating immune complexes was supported by in vitro
and in vivo studies. In vitro, it was found that collagen and
collagen-like material in glomerular basement membrane have a
particular affinity for DNA (mainly for ss DNA) [591. Since
DNA is negatively charged it was thought that it binds to some
sites of glomerular basement membrane through electrostatic
forces. Moreover, DNA which was already bound to collagen is
very efficient at binding anti-DNA Ab to form immune com-
plexes; conversely preformed DNA-anti-DNA complexes can-
not be bound to the same extent to collagen. This fact repre-
sented a possible basis for a local formation of DNA-anti-DNA
complexes in lupus diseases. An experimental model implying
that such a mechanism might be at work in vivo was reported
[37, 60, 611. Injection of lipopolysaccharide (LPS) in mice
induced in the first 24 hours the release of a high amount of
circulating DNA in blood; then after three days, the appearance
of anti-DNA Ab; lastly the deposition in glomeruli of immune
complexes and complement. Immunochemical studies revealed
that a high percentage of the immunoglobulins eluted had
anti-ss DNA activity and that these antibodies were concen-
trated in glomeruli as compared to serum. In serum, DNA-anti-
DNA complexes were not detected. While the possibility of a
direct deposition of immune complexes cannot be ruled out, all
these results were consistent with a mechanism of local forma-
tion of DNA-anti-DNA complexes in lupus diseases. It is now
commonly accepted that such a mechanism might be at work in
human pathology in the formation of mesangial, subendothelial
and subepithelial immune complexes [621. It has been well
documented in some animal models, particularly in the study
reported by Golbus and Wilson [631 using concanavalin A as a
planted antigen. However, further attempts failed to demon-
strate experimentally the local formation of DNA-anti-DNA
immune complexes [64, 65]. O'Regan and Turgeon [661 re-
ported the in situ formation of DNA-anti-DNA immune com-
plexes in the rabbit, but due to the high amount of DNA infused
in kidneys the relevance of these findings to human pathology
should be questioned.
Therefore, if there is some evidence that DNA-anti-DNA
complexes are present in glomeruli during lupus diseases, the
mechanism by which they accumulate in kidneys remains
unknown. Still the possibility exist that both mechanisms
(deposition of circulating complexes and local formation) might
be simultaneously or successively involved in the same patient
or, that these different mechanisms might be at work in different
patients. Moreover, other pathogenic mechanisms might play a
significant role in the development of lupus nephritis, leading to
the next question.
What is the pathophysiological importance of DNA-anti-DNA
complexes as compared with other possible
pathogenic mechanisms?
While many auto-antibodies systems other than DNA have
been discovered since the 1970's, few have been investigated at
the renal level in as intense a fashion as DNA. In SLE patients,
it has been suggested that other immune complex systems
involving rheumatoid factors, or nuclear antigens other than
DNA [67] might participate in the pathogenesis of lupus nephri-
tis. In one study, antibodies to the cytoplasmic antigen Ro have
been demonstrated to be enriched in eluates of lupus patients
kidneys, in the absence of detectable anti-DNA antibodies [681.
The extent to which such systems might be involved in lupus
nephritis is still unknown. In various strains of mice with
spontaneous lupus-like syndromes, it has been strengthened
that the DNA-anti-DNA system plays a pathogenic role [69] and
that immune complexes involving viral antigens or related
proteins such as gp7O, do not play an important role [701.
Idiotype-antiidiotype immune complexes might also be depos-
ited in glomeruli during lupus diseases. Experimental data on
Balb/c mice supported such a possibility [71]. More recently,
cross reactive anti-DNA Ab idiotypes have been identified on
tissue-bound immunoglobulins in about half of renal biopsies
from 26 SLE patients studied [72].
Recent evidences for the polyspecificity of anti-DNA Ab
have suggested that they might be pathogenic through mecha-
nisms independent of DNA-anti-DNA complexes formation.
Indeed, studies done with monoclonal anti-DNA Ab of human
and mouse origin have shown that they are able to bind to
various molecules including phospholipids, such as cardiolipin
[73, 74], proteoglycans [75], cytoskeletal proteins (notably, the
intermediate filament vimentin) [76], immunoglobulins [77], and
cell membrane polypeptides [78—80]. These findings raises the
question of a possible pathogenic role of these auto-antibodies
through their binding to some non-nuclear tissue or cellular
component, but at the present time no support for such an
hypothesis is available despite various experimental attempts
[28].
In conclusion there is no definite answer to the questions
posed, but the data presently available can be interpretated as
supporting the view that DNA-anti-DNA complexes play a
major or at least a significant pathogenic role in the develop-
ment of lupus nephritis. In that respect, direct studies on
circulating DNA were obviously needed to better understand
what might be the origin and the pathophysiological significance
of anti-DNA Ab in lupus diseases.
Circulating DNA in tupus diseases
First reports on the presence of circulating DNA during the
course of lupus diseases
In 1966 Tan et al [42] selected SLE sera with precipitating
anti-DNA Ab and used them in a gel diffusion method to detect
and characterize DNA in other SLE sera. Increased levels of
native (ds) DNA were detected in some lupus patients. DNA
was not found in normal sera but was detected in patients with
various malignant and liver diseases. In two follow-up studies
the presence of DNA in serum was found to corrolate with
exacerbation of lupus nephritis. In one patient, anti-DNA Ab
were detected in samples collected before DNA appeared. It
was concluded that immune complexes of potential significance
to the renal lesions may have been formed. Soon after this
report (as previously discussed), evidence for the deposition of
DNA-anti-DNA complexes in kidneys from lupus patients
became available from immunopathological studies. In 1968 the
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presence of circulating DNA was also found in sera from
NZBxNZW female mice [7],
Controversy on the detection and sign jficance of circulating
DNA in serum
In 1973, using an assay based on the inhibition of hemagglu-
tination, circulating ss DNA was reported to occur in about 50%
of patients suffering from SLE and from rheumatoid arthritis
[81]. However, mean concentration of DNA in positive sera
was higher in SLE patients (53 tg/ml) than in patients with
rheumatoid arthritis (14 g/m1). Serum DNA (> 0.4 g/m1) was
also found in 7 out of 56 normal human sera. Results from
follow-up studies reported in this paper as well as those
reported simultaneously by Harbeck et al [48], further sup-
ported the view that extracellular DNA was present in blood
and that it may play a pathogenic role through the formation of
circulating DNA-anti-DNA complexes. However, almost
simultaneously Davis and Davis [57], using a technique of
counter immunoelectrophoresis, reported that the presence of
DNA in serum might be, at least in part, related to the release
of DNA during clotting. This finding was confirmed by
Steinman in 1975 [35]. In this study, DNA was specifically
detected in most sera tested while no DNA was found in plasma
samples. It was concluded that: (1) circulating DNA must be
measured in plasma and not in serum; (2) the presence in
plasma of ds DNA in amounts greater than 50 ng/ml or of ss
DNA in amounts greater than 100 ng/ml was abnormal. These
values were later confirmed by Dennin [82] who combined
CsCI-buoyant density centrifugation and electron microscopy
to study the concentration and length distribution of circulating
DNA in human plasma. In five healthy subjects, DNA concen-
tration was found to be in the range of 3 to 11 nglml. These
findings strengthened the view that results obtained in serum
samples must be analyzed with caution [56]. In fact, release of
DNA during clotting (or DNA from infectious agents grown in
serum even stored at 4°C) may lead to the artefactual formation
in the sample of DNA-anti-DNA immune complexes, which are
easily detected in a conventional Farr assay by DNase diges-
tion.
It should be stressed that despite the nature of the sample,
results obtained in serum samples from lupus patients might
have some pathogenic significance, since circulating DNA was
found more frequently and in higher levels in those patients
than in normal controls. In our opinion, these results clearly
indicated that in some pathological situations, particularly in
systemic lupus, white blood cells are fragile and/or damaged,
and therefore are prone to disruption during blood clotting. The
extent to which such a phenomenon might also occur during
blood collection and centrifugation for obtaining plasma should
be questioned. Surprisingly, the pathogenic significance of this
phenomenon has never been studied, while it might provide a
key for the systemic or local release of nuclear (and cytoplas-
mic) antigens and the subsequent formation of immune com-
plexes.
Further studies on circulating DNA
Plasma levels of circulating DNA in lupus diseases. As soon
as the technical problems dealing with the specificity of the
assays used to detect DNA and with the artefactual release of
DNA in serum samples during clotting were clarified, circulat-
ing DNA was studied in SLE. Plasma samples were examined
by a modified counter-immunoelectrophoresis assay capable of
detecting 20 ng/ml of ds-DNA [83]. Circulating DNA was found
on several separate occasions in most (16 of 20) patients with
central nervous system involvement and/or systemic vasculitis.
In contrast, only 1 out of 18 patients with active SLE but
without these manifestations had circulating DNA. Two further
studies were done after extraction and concentration of DNA
from plasma samples. In the first one, Raptis and Menard [84],
using the technique of in vitro DNA labelling by Nick Transla-
tion to measure DNA, found that there was no difference in
plasma DNA concentration found in normal individuals, and in
patients with a chronic inflammatory disease or with inactive
lupus. In contrast, plasma DNA concentration was found to be
considerably higher in two not treated, newly diagnosed active
SLE patients. Both had decreased C3 levels and elevated serum
ds DNA binding activity. Neither had central nervous system
involvement or features suggestive of chronic vasculitis. In the
second one, DNA levels were semi-quantitatively estimated by
counter-immunoelectrophoresis [85]. DNA was found in 22
normal people within a range of 4 to 13 nglml and in 30 SLE
patients within a range of 4 to 400 ng/ml, In SLE patients,
plasma DNA concentrations correlated inversely with titers of
anti-DNA Ab. No correlation was found between levels of
DNA or anti-DNA Ab and the presence of active nephritis.
More recently a new method of quantitation of DNA plasma
which detects free as well as complexed DNA, whatever its
physicochemical characteristics, was developed [86]. Mean
normal levels in human plasma were found to be around 10
ng/ml. Increase of plasma levels of DNA was correlated with an
exacerbation of SLE [87]; the association of high levels of
plasma DNA with anti-ds-DNA Ab was found more often in
patients with diffuse proliferative glomerulonephritis than in
patients with other types of renal lesions. Follow-up studies
showed that exacerbation of the disease can occur when anti-ds
DNA Ab are undetectable. In such cases, plasma DNA levels
were always increased. By contrast, when anti-ds DNA Ab
levels were raised in a patient in remission, plasma DNA levels
were consistently normal (Fig. 1).
Studies of circulating DNA in other pathological situations
clearly indicated that the increase in levels of circulating DNA
is a non-specific phenomenon related to cytolysis. Increase in
plasma DNA has been found in various pathological situations.
The presence of high amounts of circulating DNA during
hemodialysis, first reported by Steinman and Ackad in 1977 [38]
is now well established. It has also been reported in patients
suffering from tumors [88], phlebitis and pulmonary embolism
[57, 89] and in post-operative surgical patients [57]. More
important has been the finding that increases in plasma DNA
were found in non-SLE patients suffering from disorders similar
to those found in SLE patients. This is the case in patients
suffering from systemic vasculitis and in patients with chronic
glomerulonephritis. Steinman, using the technique of counter-
immunoelectrophoresis, found circulating DNA in most (42 of
47) plasmas from 16 patients suffering from polyarteritis nodosa
and related syndromes with vasculitis [90]; in contrast, plasma
DNA was not usually detected in plasma from normal individ-
uals or from patients with other systemic inflammatory dis-
eases. Similarly, increased levels of plasma DNA have been
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found in some patients suffering from chronic glomerulonephri-
tis (Fournié et a!, unpublished data). As in patients suffering
from lupus nephritis, increase in plasma DNA was found more
often when glomerular lesions were severe with cellular prolif-
eration than when not (Fig. 2).
From all these data it can be concluded that the increase in
plasma DNA is a non-specific phenomenon related to cytolysis,
which is found in many pathological situations such as leuke-
mia, myocardial infarction, viral infections or graft versus host
reaction (Fournié et al, unpublished data). Experimental studies
done in LPS injected mice [37, 86], in hairless mice irradiated
by ultraviolet light (Luld J et al, unpublished data), as well as in
nude mice bearing solid human tumors [91] further support this
view.
Characterization of circulating DNA. The powerful tech-
niques of molecular biology have been applied to the study of
circulating DNA. Such techniques might help to elucidate the
origin, and the molecular and physicochemical properties of
circulating DNA. Inmost of the works performed at the present
time, and based on physicochemical and molecular studies of
DNA or on hybridization experiments, the DNA circulating in
blood from lupus patients has been found to be from host origin
[84, 92, 93]. The size of circulating DNA has also been studied
[93—96]. DNA fragments of well characterized size ranging from
20 to 25 base pairs to several hundred base pairs have been
characterized. Unfortunately, most of these studies have been
done on serum samples after precipitation of "complexed
DNA" by ammonium sulfate or polyethylene glycol. The
significance of these results in relation to the real presence of
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Fig. 1. Follow-up study of plasma DNA (,
ng/ml) and anti-double stranded DNA
antibodies (anti-ds DNA Ab) (. o.
% DNA ppt) in six lupus patients with
glomerulonephritis. Left: 3 patients with
active proliferative glomerulonephritis; right: 3
patients under remission (Anti-ds DNA Ab
levels are expressed in % of radiolabelled
DNA precipitated in a conventional Farr's
radioimmunoassay).
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Fig. 2. Levels of plasma DNA in relation to histopathological findings
in 35 SLE patients. Abbreviations are: (left) mm., minimal changes;
mes., mesangial; m., extramembranous; s.f., segmental and focal; g.d.,
global and diffuse and in 88 patients with primary chronic glomerulo-
nephritis (G.N.), (right) IgA, 1gM, glomerulonephritis with IgA or 1gM
deposits; m., extramembranous; X., various types of primary chronic
G.N. without cellular proliferation; m.p., membrano-proliferative; r.p.,
rapidly progressive; —, glomerulonephritis without cellular prolifera-
tion; +, glomerulonephritis with cellular proliferation. Dotted line
represented the upper limit of normal values (25 ng/ml). Histopatholog-
ical studies were done by Mrs. Madeleine Mignon-Conte.
100
50
0...
D. .
I I
.00
I.. I •—-—.I
1000
1 year Time, years
•
S
S
S
S S SS
• S
S
• S
..._,
•
• S
S
S S•
S
•••
.E EEE 0)
—I
4 EX < 429E..
+
SLE Primary chronic GN
-6O3'.
,310
'281.
271
234
p118
.I
4-
I.IA LI
-72
fragments of approximately 150 base pairs were also character-
ized in the supernatant from cultured splenocytes [97].
The DNA isolated from plasma and from cell free supernatant
from cultured splenocytes was sensitive to DNase treatment
and resistant to Si nuclease digestion, leading to the conclusion
that it was double stranded. Moreover, the base composition of
plasma DNA was studied in two independent studies [93, 98],
one of which was based on cloning of serum DNA into phage M
13 and on sequencing of 10 randomly selected recombinants
[98]. The average guanine-cytosine content of serum DNA was
found to be higher than that of total human DNA (around 45%
vs. 38%). The possibility that Z-DNA forming regions were
present in this DNA and might be responsible for the induction
of anti-Z-DNA antibodies was underlined. The fact that ribo-
somal DNA is known to be rich in guanine-cytosine content [99]
was not discussed in these studies. Besides, it might also be
interesting to note that antibodies to RNA polymerase I, an
enzyme of nucleolar origin, are present in most (if not all) lupus
patients [100].
In the majority of the studies dealing with the characteriza-
tion of the size of extracellular DNA, a well defined band of
DNA sizing around 200 base pairs was found whatever the
plasma or serum origin of the sample. In our hands (Laval et al,
unpublished data), this band (from 120 to 200 base pairs) has
been found in plasma from mouse and human lupus diseases as
well as in all of the other pathological situations characterized
by an increase in levels of plasma DNA that we have been able
to study (Fig. 3).Several arguments suggest that in all these
situations, including lupus diseases, extracellular DNA might
represent some products of the catabolism of chroniatin: (1)
The size of the "major band" is that of the DNA bound to the
core histones in nucleosomes [101]. Bands of higher molecular
weight, the size of which fit with the size of polynucleosomes
are frequently found. In some cases, we have also characterized
well defined bands of DNA of lower molecular weight which
might be the result of the partial digestion of nucleosomic DNA
at sites more prone to nuclease digestion [102]. (2) These
patterns have been found in several human and murine patho-
logical situations, the only common feature of which is
cytolysis. (3) Preliminary results obtained in our laboratory
suggested that circulating DNA might be precipitated in vitro by
IgG with anti-histone activity, suggesting that extracellular
DNA might circulate in blood as nucleosomes.
Conclusions and hypotheses
In the light of the data we have presented and discussed, it is
now possible to have some new insights on the two basic
questions previously raised.
Is extracellular DNA responsible for the induction of
anti-DNA antibodies?
It is clear from several experimental works that injections of
purified DNA, even with conventional adjuvant, cannot induce
significant levels of anti-DNA Ab. In fact, in vivo, pure mole-
cules of DNA are unlikely to be present, and due to the
presence in blood and in tissues of various potent nucleases, to
be immunogenic. It is possible that in vivo DNA is rendered
immunogenic and protected from nuciease digestion through its
Fig. 3. Characterization of the size of plasma DNA in various human
and experimental situations: LED, lupus patients; Nd, patients under
hemodialysis; NMP, normal mouse plasma; NZ, NZBxNZW mice;
LPS, mice injected with lipopolysaccharide; Std, DNA from X 174 RF
digested by Hae 111 (size of fragments are indicated in number of
nucleotides); UV, hairless mice irradiated by ultra violet light;
Nude/H,tumor, nude mice transplanted with solid human tumors.
Plasma DNA was purified and radiolabelled with 32P using a 3' end
labelling technique. Eight percent polyacrylamide gel electrophoresis in
6 at urea. Molecular characterization of plasma DNA has been done by
Mrs. Francoise Laval.
binding to some DNA binding proteins. It is well established
that anti-DNA Ab (directed against ss DNA) can be easily
induced when DNA is complexed to basic proteins, such as
methylated bovine serum albumin [103]. In the mouse, anti-
DNA antibodies can also be induced by injection of bacterial
lipopolysaccharide (LPS) [37]. In this model, the polyclonal
activation of lymphocytes induced by LPS is involved in the
production of anti-DNA Ab [1041. However, experimental data
support the view that the induction of anti-DNA Ab is depen-
dent on the specific recruitment of anti-DNA Ab secreting
clones of lymphocytes under the simultaneous actions of DNA
and of LPS [105]. In such situations characterized by the
release in blood of products of cytolysis [37, 86], DNA can be
bound to DNA binding proteins, which might make it more
492 Fournié: Circulating DNA and lupus nephritis
circulating DNA should therefore be questioned. Besides, DNA LED Hd NMP NZ LPS Std. UV Nude/H.tumor 11201 - r..
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immunogenic and/or more resistant to some metabolic path-
ways. The association of DNA and DNA-binding proteins
might therefore favor, under suitable conditions (such as a
predisposed genetic background and/or a polyclonal activation
of lymphocytes) the induction of antibodies directed against
DNA. If such an hypothesis is valid, there should be found at
the same time antibodies directed against the DNA-binding-
proteins associated in the complex. This might be the case for
RNA polymerase I and histones. Indeed, Stetler and Jacob
found that immunization of rabbits with purified RNA polymer-
ase I induces two distinct populations of antibodies directed
against the triggering antigen on one hand, and nucleic acids on
the other hand [106]. In lupus patients, the presence of antibod-
ies to prominent histones of the chromatine structure has been
underlined by Hardin and Thomas [107], leading to the hypoth-
esis that nucleosomes might well represent an immunogen at
work in lupus diseases besides other, well characterized nuclear
antigen-antinuclear antibody or cytoplasmic antigen-anticy-
toplasmic antibody systems [108]. Investigations done in
murine graft-versus-host disease also support this possibility. In
this lupus-like disorder, characterized by the production of
antinuclear antibodies and the development of a severe immune
complex-mediated renal disease [109], it has been found that
antibodies to histone and DNA were selectively produced [110].
A similar mechanism might occur in another mouse model of
lupus disease observed after neonatal induction of transplanta-
tion tolerance [1111. These facts, as well as the results on the
molecular size of plasma DNA previously discussed, suggest
that anti-DNA Ab production might be triggered by some
products of catabolism of nuclei from dead cells, particularly by
the chromatin itself.
Alternatively, it has been suggested that the immunogen
triggering anti-DNA Ab might be unrelated to nuclear antigens
(and that anti-DNA Ab might play some pathogenic role
through binding to some antigens present in tissues or on cell
membranes) [79]. For example, it has been found that normal
mice immunized with a cardiolipin-protein conjugate responded
by producing both anti-cardiolipin and anti-DNA Ab [1121. The
relevance of the cross-reactions of anti-DNA Ab with other
antigens to the genesis of anti-DNA Ab should be questioned.
Quantitative analysis of anti-DNA Ab specificity in solution
indicated that the apparent cross-reactivity of anti-DNA Ab in
solid phase assays may not represent a physiologically relevant
interaction between anti-DNA Ab and non-nucleic acid anti-
gens [113]. These results cannot exclude this alternative mech-
anism of anti-DNA Ab induction, particularly in the light of the
demonstration of anti-DNA Ab binding peptides at the cell
surface [78, 79]. However, the possibility that such peptides
might trigger the induction of anti-DNA Ab has not been yet
reported. Furthermore, the wide spectrum of antinuclear and
anticytoplasmic antibodies found in blood from lupus patients
strongly suggest that agents which trigger the induction of these
various sets of auto-antibodies are products of cell catabolism
after cytolysis.
Taken together, all the data presently available are consist-
ent, in our opinion, with the hypothesis that chromatin might
well represent the immunogen at work in the triggering of
anti-DNA Ab under particular conditions related to a predis-
posed genetic background. This hypothesis implies that most, ii
not all, the studies done until now on the catabolism of DNA
(which have been done with purified DNA) are not relevant to
the physiopathology of lupus diseases. In fact the persistence of
high levels of circulating DNA during a long period of time
cannot be explained in several situations ii one takes into
account that (as clearly demonstrated) the half life in blood of
pure extracellular DNA is in the order of magnitude of a few
minutes at most. Studies of chromatin metabolism are needed
to challenge the above hypothesis.
Does extracellular DNA play a pathogenic role in the
development of glomerular lesions?
Following the hypothesis previously made, it should be said
that if circulating DNA (in fact circulating chromatin) is the
witness of cell death, the potential pathogenic significance of
this phenomenon should be analyzed in the light of cytolysis
and of catabolism of chromatin. Assuming that one cell contains
about 10 pg of DNA, the catabolism of chromatin of one cell
should provide more than io molecules of 200 base pairs.
Therefore it seems highly possible that the phenomenon of cell
death either in circulation or in tissues might provide antigens in
sufficient amount to lead to the formation of immune complexes
and, through the activation of the complement system, to tissue
lesions. Recent studies on the size of DNA fragments which can
be bound by anti-DNA Ab [114] and might activate the com-
plement system [115, 116] are consistent with such an hypoth-
esis. Previous histopathological and cytochemical studies on
kidneys and other tissues from SLE patients also support this
hypothesis [117—120]. Indeed, the presence of Gross hematox-
ylin bodies, which are the counterpart in tissues of the LE
phenomenon described by Hargraves in vitro, is a well known
criteria of severe active lupus glomerulonephritis [121].
Besides, one cannot exclude, as previously discussed, that
anti-DNA Ab might play their pathogenic role through binding
to some cross-reacting antigenic structure present in tissue or
cellular membrane. In that respect, the presence of nuclear
antigens, of peptides reacting with anti-DNA antibodies, and of
receptors for DNA on the membranes of various cells [71, 122]
should be remembered. They might be the target for some
antinuclear antibodies leading to cytolysis and to the subse-
quent release in blood or in situ of "antigenic material" to
which antinuclear antibodies might bind. It is therefore possible
that the same antibody population might play a pathogenic role
at two levels by binding different antigens located on cell
membrane and nuclear structures. Studies done on SLE sera
which contain antinuclear antibodies reacting specifically with
both core mononucleosomes and plasma membranes of viable
nucleated cells (and which might be identical with the LE
factor) support such a possibility [1231.
Is there an impairment of chromatin catabolism in
lupus diseases?
Since many situations characterized by cytolysis are not
followed by the induction of anti-DNA Ab, it has been
hypothetized that a genetic predisposition to make such anti-
bodies might play a role in the development of lupus diseases.
Alternatively a defect in the catabolism of chromatin has also
been suggested to be involved [120]. Indeed, it is obvious that
such a defect might enhance the immunogenic properties of
DNA in chromatin and/or might favor the persistence of rele-
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vant antigens in blood or in tissues to be accessible to specific
autoantibodies. While this possibility remains at the present
time purely speculative, it should be noted that levels of
C-reactive protein, which has been shown to mediate the
solubilization of nuclear DNA by complement in vitro [124,
1251, have been found to be decreased in three out of eight SLE
patients [124]. Since the complement system is involved in the
solubilization of chromatin, one might also question if an
inability to solubilize chromatin could be one of the reasons
why patients suffering from inherited deficiencies of the com-
plement system are prone to develop lupus type of auto-
immune diseases [126].
To conclude, we hope that in the near future studies on
cytolysis phenomena and on the catabolism of chromatin in
lupus diseases as well as in other pathological and experimental
situations will be designed to challenge the physiopathological
hypothetical mechanisms we have presented and discussed.
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